Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Autoimmune Encephalitis Misdiagnosis in Adults
Geschwind, Michael D. , López‐Chiriboga, A. Sebastian , Blackburn, Kyle , Turaga, Sanchit, Binks, Sophie , Day, Gregory S. , Rodenbeck, Stefanie, Clardy, Stacey , Solomon, Andrew , Pittock, Sean J. , Dubey, Divyanshu , Ζεκερίδου, Αναστασία , Toledano, Michel , Turner, Lindsey E., Vernino, Steven , Irani, Sarosh R. , Pittock, S J , Irani, Sarosh R , Clardy, Stacey L , Day, Gregory S , Dubey, Divyanshu , Binks, Sophie N M , Vernino, Steven , Flanagan, Eoin P. , Zitser, Jennifer , Gelfand, Jeffrey M. , Dunham, Steven , McKeon, Andrew

Mayo Clinic

JAMA Neurology | November 28, 2022 | Volume: 80 | Issue: 1 | Pages: 30

10.1001/jamaneurol.2022.4251 | PMID 36441519 Get It

ImportanceAutoimmune encephalitis misdiagnosis can lead to harm.ObjectiveTo determine the diseases misdiagnosed as autoimmune encephalitis and potential reasons for misdiagnosis.Design, Setting, and ParticipantsThis retrospective multicenter study took place from January 1, 2014, to December 31, 2020, at autoimmune encephalitis subspecialty outpatient clinics including Mayo Clinic (n = 44), University of Oxford (n = 18), University of Texas Southwestern (n = 18), University of California, San Francisco (n = 17), Washington University in St Louis (n = 6), and University of Utah (n = 4). Inclusion criteria were adults (age ≥18 years) with a prior autoimmune encephalitis diagnosis at a participating center or other medical facility and a subsequent alternative diagnosis at a participating center. A total of 393 patients were referred with an autoimmune encephalitis diagnosis, and of those, 286 patients with true autoimmune encephalitis were excluded.Main Outcomes and MeasuresData were collected on clinical features, investigations, fulfillment of autoimmune encephalitis criteria, alternative diagnoses, potential contributors to misdiagnosis, and immunotherapy adverse reactions.ResultsA total of 107 patients were misdiagnosed with autoimmune encephalitis, and 77 (72%) did not fulfill diagnostic criteria for autoimmune encephalitis. The median (IQR) age was 48 (35.5-60.5) years and 65 (61%) were female. Correct diagnoses included functional neurologic disorder (27 [25%]), neurodegenerative disease (22 [20.5%]), primary psychiatric disease (19 [18%]), cognitive deficits from comorbidities (11 [10%]), cerebral neoplasm (10 [9.5%]), and other (18 [17%]). Onset was acute/subacute in 56 (52%) or insidious (>3 months) in 51 (48%). Magnetic resonance imaging of the brain was suggestive of encephalitis in 19 of 104 patients (18%) and cerebrospinal fluid (CSF) pleocytosis occurred in 16 of 84 patients (19%). Thyroid peroxidase antibodies were elevated in 24 of 62 patients (39%). Positive neural autoantibodies were more frequent in serum than CSF (48 of 105 [46%] vs 7 of 91 [8%]) and included 1 or more of GAD65 (n = 14), voltage-gated potassium channel complex (LGI1 and CASPR2 negative) (n = 10), N-methyl-d-aspartate receptor by cell-based assay only (n = 10; 6 negative in CSF), and other (n = 18). Adverse reactions from immunotherapies occurred in 17 of 84 patients (20%). Potential contributors to misdiagnosis included overinterpretation of positive serum antibodies (53 [50%]), misinterpretation of functional/psychiatric, or nonspecific cognitive dysfunction as encephalopathy (41 [38%]).Conclusions and RelevanceWhen evaluating for autoimmune encephalitis, a broad differential diagnosis should be considered and misdiagnosis occurs in many settings including at specialized centers. In this study, red flags suggesting alternative diagnoses included an insidious onset, positive nonspecific serum antibody, and failure to fulfill autoimmune encephalitis diagnostic criteria. Autoimmune encephalitis misdiagnosis leads to morbidity from unnecessary immunotherapies and delayed treatment of the correct diagnosis.
Development and application of a computable genotype model in the GA4GH Variation Representation Specification
Goar, Wesley , Babb, Lawrence , Cline, Melissa , Kuzma, Kori , Lee, Jennifer , Nelson, Tristan , Smith, Anastasia , Stahl, Kathryn , Bratulin, Anastasia L. , Babb, Lawrence , Chamala, Srikar , Freimuth, Robert R. , Hart, Reece K. , Prlić, Andreas , Riehle, Kevin P. , Yates, Andrew , Rehm, Heidi L. , Wagner, Alex H.

Mayo Clinic

Biocomputing 2023 | November 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: 383-394

10.1142/9789811270611_0035 Get It

Genetic therapy in a mitochondrial disease model suggests a critical role for liver dysfunction in mortality
Sabharwal, Ankit , Wishman, Mark , Cervera, Roberto Lopez , Serres, MaKayla R., Anderson, Jennifer L. , Holmberg, Shannon R. , Treichel, Anthony J. , Ichino, Noriko , Liu, Weibin , Yang, Jingchun , Deng, Yun , Lacey, Jean M., Laxen, William , Loken, Perry R , Oglesbee, Devin , Wishman, Mark D, Treichel, Anthony J , Ichino, Noriko , Ding, Yonghe , Laxen, William J, Farber, Steven Arthur , Clark, Karl J , Lin, Xueying , Ekker, Stephen C , Oglesbee, Devin , Sabharwal, Ankit , Kar, Bibekananda , Kar, Bibekananda , Farber, Steven , Clark, Karl J. , Xu, Xiaolei , Ekker, Stephen C.

Mayo Clinic

eLife | November 21, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.65488 | PMID 36408801 Get It

The clinical and largely unpredictable heterogeneity of phenotypes in patients with mitochondrial disorders demonstrates the ongoing challenges in the understanding of this semi-autonomous organelle in biology and disease. Previously, we used the gene-breaking transposon to create 1200 transgenic zebrafish strains tagging protein-coding genes (Ichino et al., 2020), including the lrpprc locus. Here, we present and characterize a new genetic revertible animal model that recapitulates components of Leigh Syndrome French Canadian Type (LSFC), a mitochondrial disorder that includes diagnostic liver dysfunction. LSFC is caused by allelic variations in the LRPPRC gene, involved in mitochondrial mRNA polyadenylation and translation. lrpprc zebrafish homozygous mutants displayed biochemical and mitochondrial phenotypes similar to clinical manifestations observed in patients, including dysfunction in lipid homeostasis. We were able to rescue these phenotypes in the disease model using a liver-specific genetic model therapy, functionally demonstrating a previously under-recognized critical role for the liver in the pathophysiology of this disease.
Impact of the COVID ‐19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race
Berrian, Jennifer L. , Ezenwajiaku, Nkiruka, Moreno‐Aspitia, Alvaro , Toriola, Adetunji T. , Colditz, Graham A. , Housten, Ashley J. , Hall, Lannis, Fiala, Mark A. , Holton, Sara J, Toriola, Adetunji T , Colditz, Graham A , Housten, Ashley J , Ademuyiwa, Foluso O , Fiala, Mark A , Liu, Ying , Holton, Sara J., Ademuyiwa, Foluso O.

Mayo Clinic

Cancer Medicine | November 21, 2022 | Volume: 12 | Issue: 6 | Pages: 7381-7388

10.1002/cam4.5439 | PMID 36404491 Get It

Abstract Purpose To determine if the COVID‐19 pandemic has further exacerbated racial disparities in late‐stage presentation of breast, colorectal, lung, and prostate cancers. Methods We conducted a registry‐based retrospective study of patients with newly reported diagnoses of breast, colorectal, lung, and prostate cancers between March 2019–June 2019 (pre‐COVID‐19) and March 2020–June 2020 (early‐COVID‐19). We compared the volume of new diagnoses and stage at presentation according to race between both periods. Results During the study period, a total of 3528 patients had newly diagnosed cancer; 3304 of which had known disease stages and were included in the formal analyses. 467 (14.1%) were Blacks, and 2743 were (83%) Whites. 1216 (36.8%) had breast, 415 (12.6%) had colorectal, 827 (25%) had lung, and 846 (25.6%) had prostate cancers, respectively. The pre‐COVID‐19 period included 2120 (64.2%), and the early‐COVID‐19 period included 1184 (35.8%), representing a proportional 44.2% decline in the volume of new cases of breast, colorectal, lung, and prostate cancers, p < 0.0001. Pre‐COVID‐19, 16.8% were diagnosed with metastatic disease, versus 20.4% early‐COVID‐19, representing a proportional increase of 21.4% in the numbers of new cases with metastatic disease, p = 0.01. There was a non‐significant proportional decline of 1.9% in Black patients diagnosed with non‐metastatic breast, colorectal, lung, and prostate cancers early‐COVID‐19 ( p = 0.71) and a non‐significant proportional increase of 7% in Black patients diagnosed with metastatic disease ( p = 0.71). Difference‐in‐difference analyses showed no statistically significant differences in metastatic presentation comparing Black to White patients. Conclusion While we identified substantial reductions in the volume of new cancer diagnoses and increases in metastatic presentations due to the COVID‐19 pandemic, the impact was similar for White and Black patients.
Increasing socioeconomically disadvantaged patients’ engagement in breast cancer surgery decision-making through a shared decision-making intervention (A231701CD): protocol for a cluster randomised clinical trial
Schumacher, Jessica R. , Zahrieh, David M. , Chow, Selina , Wills, Rachel, Hanlon, Bret M. , Tucholka, Jennifer L. , Neuman, Heather B. , Hanlon, Bret M , Neuman, Heather B , Taylor, John, Rathouz, Paul J.

Mayo Clinic

BMJ Open | November 17, 2022 | Volume: 12 | Issue: 11 | Pages: e063895

10.1136/bmjopen-2022-063895 | PMID 36396308 Get It

Introduction Socioeconomic disparities for breast cancer surgical care exist. Although the aetiology of the observed socioeconomic disparities is likely multifactorial, patient engagement during the surgical consult is critical. Shared decision-making may reduce health disparities by addressing barriers to patient engagement in decision-making that disproportionately impact socioeconomically disadvantaged patients. In this trial, we test the impact of a decision aid on increasing socioeconomically disadvantaged patients’ engagement in breast cancer surgery decision-making. Methods and analysis This multisite randomised trial is conducted through 10 surgical clinics within the National Cancer Institute Community Oncology Research Program (NCORP). We plan a stepped-wedge design with clinics randomised to the time of transition from usual care to the decision aid arm. Study participants are female patients, aged ≥18 years, with newly diagnosed stage 0–III breast cancer who are planning breast surgery. Data collection includes a baseline surgeon survey, baseline patient survey, audio-recording of the surgeon–patient consultation, a follow-up patient survey and medical record data review. Interviews and focus groups are conducted with a subset of patients, surgeons and clinic stakeholders. The effectiveness of the decision aid at increasing patient engagement (primary outcome) is evaluated using generalised linear mixed-effects models. The extent to which the effect of the decision aid intervention on patient engagement is mediated through the mitigation of barriers is tested in joint linear structural equation models. Qualitative interviews explore how barriers impact engagement, especially for socioeconomically disadvantaged women. Ethics and dissemination This protocol has been approved by the National Cancer Institute Central Institutional Review Board, and Certificate of Confidentiality has been obtained. We plan to disseminate the findings through journal publications and national meetings, including the NCORP network. Our findings will advance the science of medical decision-making with the potential to reduce socioeconomic health disparities. Trial registration number ClinicalTrials.gov Registry (NCT03766009).
Antibodies as drugs—a Keystone Symposia report
Cable, Jennifer, Wiltshire, Timothy D. , Mousa, Jarrod J. , Humphreys, David P., Breij, Esther C.W. , Bruhns, Pierre , Broketa, Matteo , Furuya, Genta , Hauser, Blake M. , Mahévas, Matthieu , Kwong, Peter D. , Davis, Jonathan H. , Brewis, Neil , Keyt, Bruce A. , Fennemann, Felix L. , Dussupt, Vincent , Rawi, Reda , Wolters, Rachael M. , Geuijen, Cecile, Sleeman, Matthew A. , Pengo, Niccolò , Donnellan, Francesca R. , Saphire, Erica Ollmann , Hayday, Adrian , Carfı́, Andrea , Cantaert, Tineke , Tripathi, Prabhanshu , Sivasubramanian, Arvind, Kim, Philip M. , Richardson, Eve , Leventhal, Daniel

Mayo Clinic

Annals of the New York Academy of Sciences | November 16, 2022 | Volume: 1519 | Issue: 1 | Pages: 153-166

10.1111/nyas.14915 | PMID 36382536 Get It

AbstractTherapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27–30, 2022, experts in antibody research across academia and industry met for the Keystone symposium “Antibodies as Drugs” to present the state‐of‐the‐art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.
Abstract A033: Gene-specific risk of syndrome-associated cancers in first-degree relatives of pancreatic cancer patients with pathogenic/likely pathogenic variants
Meyer, Margaret, Kemppainen, Jennnifer, Horibe, Masayasu, Chandra, Shruti , Majumder, Shounak, Petersen, Gloria M. , Chen, Xuan , Rabe, Kari G. , Meyer, Margaret, Kemppainen, Jennifer L., Horibe, Masayasu

Mayo Clinic

Cancer Research | November 15, 2022 | Volume: 82 | Issue: 22_Supplement | Pages: A033-A033

10.1158/1538-7445.panca22-a033 Get It

Abstract Increased pancreatic cancer (PC) risk in first-degree relatives (FDRs) of PC patients with germline pathogenic/likely pathogenic variants (PLPV) is a motivator for cascade genetic testing. To date, unbiased FDR risk estimates for gene-specific risks of genetic cancer syndrome-associated cancers are unknown. These estimates would enhance genetic counseling of at-risk FDRs in families where the PC proband has been found to carry a PLPV. Study Aim: To objectively quantify gene-specific risks of six relevant cancers among FDRs of PC patients with germline PLPV in ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, and PMS2. Methods: In the prospective, clinic-based Mayo Clinic Biospecimen Resource for Pancreas Research registry, 4,562 PC patients had previously undergone germline genetic testing for pancreatic cancer-associated genes through either research studies or clinical testing. Of these, 234 PC probands were found to carry PLPV among 9 genes of interest and had provided detailed demographic and cancer data on their FDRs by questionnaire. We focused on six cancer types (ovary, breast, uterus, pancreas, colon, and malignant melanoma) in FDRs as reported by the probands. Standardized incidence ratios estimated risk by gene of six cancers among FDRs of PC patients carrying PLPV. Results: 1,670 FDRs (mean age 58.1+17.8SD; 48.9% female) were included in the study. We found significantly increased risk of ovarian cancer in female FDRs of PC probands who carry PLPV in BRCA1 (SIR 9.49, 95%CI:3.06-22.14) or BRCA2 (3.72, 95%CI:1.36-8.11), and breast cancer risks were higher with BRCA2 (2.62, 95%CI:1.89-3.54). Uterine cancer risk was increased in FDRs of PC probands who carry PLPV for Lynch Syndrome mismatch repair (MMR) (6.53, 95%CI:2.81-12.86). PC risk was also increased (ATM 4.53, 95% CI:2.69-7.16; BRCA2 3.45, 95%CI:1.72-6.17; CDKN2A 7.38, 95%CI:3.18-14.54; PALB2 5.39, 95%CI:1.45-13.79). Increased colon cancer risk was observed in FDRs of probands who carried MMR PLPV (5.83, 95%CI:3.70-8.75), while melanoma risk was elevated for FDRs of probands with CDKN2A PLPV (7.47, 95%CI:3.97-12.77). Conclusion: PLPV in nine syndrome-associated genes in PC probands are associated with increased risk of six cancers in FDRs in PC families. The findings underscore the importance of risk estimation of various other cancers in PC families for screening, early detection, and intervention. The gene-specific quantified cancer risks for FDRs of PC patients with syndrome-associated germline PLPV can inform counseling regarding extra-PC risks when considering cascade genetic testing. Citation Format: Xuan Chen, Kari Rabe, Margaret Meyer, Jennnifer Kemppainen, Masayasu Horibe, Shruti Chandra, Shounak Majumder, Gloria Petersen. Gene-specific risk of syndrome-associated cancers in first-degree relatives of pancreatic cancer patients with pathogenic/likely pathogenic variants [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A033.
EPCO-38. TYPE B ULTRA LONG-RANGE INTERACTIONS IN PFAS (TULIPS) ARE RECURRENT EPIGENOMIC FEATURES OF PFA EPENDYMOMA
Lee, John J. Y. , Chen, Carol, Balin, Polina , Fong, Vernon , Zwaig, Melissa , Billon, Pierre, Juretic, Nikoleta , Kim, Seung‐Ki , Wang, Kyu‐Chang , Ellezam, Benjamin , Majewski, Jacek , Johnston, Michael J.G. , Hu, Bo , Nikolić, Ana , Baguette, Audrey , Paik, Seungil , Chen, Haifen, Kumar, Sachin A. , Jessa, Selin , Michealraj, Kulandaimanuvel Antony , Chen, Xun , Zhang, Yanlin , Varadharajan, Srinidhi , Daniels, Craig, Giannini, Caterina , Thompson, Eric M. , Hauser, Péter , Lee, Ji Yeoun , Grajkowska, Wiesława , Agnihotri, Sameer , Mack, Stephen C. , Weil, Alexander G. , Bourque, Guillaume , Chan, Jennifer Ai-wen , Lupien, Mathieu , Ragoussis, Jiannis , Kleinman, Claudia L. , Jabado, Nada , Taylor, Michael D. , Blanchette, Mathieu , Gallo, Marco

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii124-vii124

10.1093/neuonc/noac209.472 Get It

Abstract Posterior Fossa Group A (PFA) ependymomas are pediatric brain tumors with extremely poor survival outcomes. As protein-coding mutations in PFA are exceedingly rare, the underlying etiology of these tumors remains elusive. Elevated CpG island methylation and depletion of H3K27me3 have been described in PFA, leading to the hypothesis that PFA may be driven by a dysregulated epigenetic state. In this study, we sought to determine how three-dimensional (3D) genome features (such as DNA loops, domains, and compartments) differ between pediatric brain tumors. We performed Hi-C sequencing on a collection of 64 patient specimens and patient-derived primary cultures that collectively span multiple subgroups of ependymoma, medulloblastoma, high-grade glioma, and non-neoplastic brain. For certain samples, we further performed RNA-seq, histone modification ChIP-seq, or whole-genome bisulfite sequencing to allow multiomic data integration. Overall, the 3D genome organization of PFA samples appeared distinct from other tumor types. We identified and defined TULIPs: a subset of type B compartments, separated by genomic distances greater than 10 Mbp, that exhibit a striking fivefold increase in reciprocal interaction strength. These TULIPs recurred at the same genomic positions across the vast majority of PFA samples with minimal representation among other tumor or non-tumor samples. TULIPs displayed enrichment for heterochromatic features such as H3K9me3 and late replication timing and were depleted of euchromatic features such as H3K27ac and protein-coding genes. By using immuno-fluorescence for H3K9me3 and oligo-FISH to label TULIP regions, we demonstrated that TULIP regions are more compact in PFA than other tumors. Finally, by applying inhibitors of H3K9 lysine methylation to PFA cultures we showed that TULIPs become more diffuse and cell viability is reduced. Altogether, this work defines TULIPs as highly recurrent epigenetic features of PFA tumors.
Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship
Vegunta, Suneela , Kuhle, Carol L. , Vencill, Jennifer A. , Lucas, Pauline , Mussallem, Dawn M. , Lucas, Pauline H.

Mayo Clinic

Journal of Clinical Medicine | November 14, 2022 | Volume: 11 | Issue: 22 | Pages: 6723

10.3390/jcm11226723 | PMID 36431200 Get It

Breast cancer is the most common cancer in women. The life expectancy after a breast cancer diagnosis is improving steadily, leaving many more persons with the long-term consequences of treatment. Sexual problems are a common concern for breast cancer survivors yet remain overlooked in both the clinical setting and the research literature. Factors that contribute to sexual health concerns in breast cancer survivors are biopsychosocial, as are the barriers to addressing and treating these health concerns. Sexual health needs and treatment may vary by anatomy and gender. Multidisciplinary management may comprise lifestyle modifications, medications, sexual health aids such as vibrators, counseling, and referrals to pelvic health physical therapy and specialty care. In this article, we review the contributing factors, screening, and management of sexual difficulties in cisgender female breast cancer survivors. More information is needed to better address the sexual health of breast cancer survivors whose sexual/gender identity differs from that of cisgender women.
The Rise of Medicare Advantage
Wang, Jennifer C. , Chen, Xiao T. , Callaghan, John J. , Berry, Daniel J. , Christ, Alexander B. , Heckmann, Nathanael D. , Chen, Xiao T , Bedard, Nicholas A. , Callaghan, John J , Berry, Daniel J , Christ, Alexander B , Heckmann, Nathanael , Piple, Amit S.

Mayo Clinic

Journal of Bone and Joint Surgery | November 11, 2022 | Volume: 104 | Issue: 24 | Pages: 2145-2152

10.2106/jbjs.22.00254 | PMID 36367757 Get It

Background: Medicare Advantage (MA) plans are popular among Medicare-eligible patients, but little is known about MA in lower-extremity total joint arthroplasty (TJA). The purpose of this study was to describe trends in MA utilization and analyze differences in patient characteristics and postoperative outcomes between patients undergoing primary TJA using traditional Medicare (TM) or MA plans. Methods: Patients ≥65 years of age who underwent primary total knee or total hip arthroplasty were identified using the Premier Healthcare Database. Patients were categorized into TM and MA cohorts. Data from 2004 to 2020 were used to describe trends in insurance coverage. Data from 2015 to 2020 were used to identify differences in patient characteristics and postoperative complications using ICD-10 codes. Multivariate analyses were performed using 2015 to 2020 data to account for potential confounders. Results: From 2004 to 2020, the proportion of patients with MA increased from 7.9% to 34.4%, while those with TM decreased from 83.7% to 54.0%. Of the 697,317 patients who underwent primary elective TJA from 2015 to 2020, 471,439 (67.6%) had TM coverage and 225,878 (32.4%) had MA coverage. The cohorts were similar in terms of age and sex. However, a higher proportion of Black patients (8.29% compared with 4.62%; p < 0.001) and a lower proportion of White patients (84.0% compared with 89.2%; p < 0.001) were enrolled in MA compared with TM. After controlling for confounders, patients with MA had higher odds of surgical site infection (adjusted odds ratio [aOR]: 1.15; 95% confidence interval [CI]: 1.04 to 1.47; p = 0.031), periprosthetic joint infection (aOR: 1.10; 95% CI: 1.03 to 1.18; p = 0.006), stroke (aOR: 1.15; 95% CI: 1.02 to 1.31; p = 0.026), and acute kidney injury (aOR: 1.08; 95% CI: 1.04 to 1.11; p < 0.001), but lower odds of urinary tract infection (aOR: 0.94; 95% CI: 0.90 to 0.98; p = 0.003). Conclusions: From 2004 to 2020, the number of patients utilizing MA increased markedly such that 1 in 3 were covered by MA in 2020. From 2015 to 2020, patients who were non-White were more likely to have MA than TM, and the MA group had a higher rate of several postoperative complications compared with the TM group. As TM claims data inform health-care policy and clinical decisions, this change portends future challenges, including limitations in arthroplasty registry research, an increase in the administrative burden of surgeons, and a potential worsening of social disparities in health care.